# Who does Yuhan Corporation pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/yuhan · Facet: suppliers · Updated: 2026-07-12T04:02:30.988+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Yuhan Corporation's confirmed suppliers/cost counterparties include 오스코텍 (렉라자 원개발사 기술료 배분) plus 3 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 4 cost edges, backed by 1 dated sources, 1 of them primary filings (as of 2026-07-12).

### Cheplapharm Arzneimittel GmbH (아타칸 수입) (high)
- metric: Amount ₩13.4B · 아타칸 매입액
- note: Imports the hypertension drug Atacand (candesartan) from Germany's Cheplapharm. 2025 purchases KRW 13.4bn (Atacand 8mg KRW 7.66bn plus 16mg KRW 5.73bn), the largest imported raw-material item.
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Imported raw materials: Atacand 8mg KRW 7,663m (6.1%) from Cheplapharm Arzneimittel GmbH; Atacand 16mg KRW 5,734m (4.6%) from Cheplapharm."

### 오스코텍 (렉라자 원개발사 기술료 배분) (high)  → /oscotec.md
- note: The original technology developer of Lazertinib. Yuhan shares part of the upfront, milestones and royalties received from Janssen with Oscotec and Genosco (commonly reported as a 6:4 split), booked as an expense.
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Fees paid to the original technology developers Oscotec and Genosco are booked as expenses; a portion of the technology fees received is shared with them under contract."

### 국전약품 (에제티미브 원료) (mid)
- metric: Amount ₩6.4B · 에제티미브 매입액
- note: Buys ezetimibe, the API for its hyperlipidemia drug Rosuvamibe, from Kukjeon Pharm and Yuhan Chemical. 2025 ezetimibe purchases KRW 6.4bn (5.1% of domestic raw materials).
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Domestic raw materials: ezetimibe (hyperlipidemia) KRW 6,413m (5.1%) from Kukjeon Pharm and Yuhan Chemical."

### ALMIRALL S.A (알마게이트 원료) (mid)
- metric: Amount ₩5.3B · 알마게이트 매입액
- note: Imports the antacid ingredient almagate from Spain's Almirall S.A. 2025 purchases KRW 5.3bn (4.2% of imported raw materials); period-end price EUR 11.00/kg.
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Imported raw materials: almagate (antacid) KRW 5,287m (4.2%) from Almirall S.A; period-end price EUR 11.00."

Reverse side: https://valuechain.wiki/yuhan/customers.md · Ripple: https://valuechain.wiki/yuhan/ripple.md

---
Full node: https://valuechain.wiki/yuhan.md · JSON: https://valuechain.wiki/yuhan.json